Hepatitis C Testing Market Report 2026

The hepatitis c testing market size has grown strongly in recent years. It will grow from $1.32 billion in 2025 to $1.4 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to expansion of blood screening programs, rising prevalence of hepatitis c infections, improved diagnostic awareness, availability of advanced testing kits, growth in public health surveillance initiatives.

The hepatitis c testing market size is expected to see strong growth in the next few years. It will grow to $1.78 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to increasing global elimination initiatives, rising demand for point-of-care diagnostics, expansion of molecular testing access, growing investments in infectious disease diagnostics, increasing focus on early intervention. Major trends in the forecast period include increasing adoption of rapid diagnostic tests, rising use of molecular testing technologies, growing focus on early disease screening, expansion of high-throughput laboratory testing, enhanced monitoring of treatment outcomes.

The increasing prevalence of hepatitis cases is anticipated to drive the growth of the hepatitis C testing market in the coming years. Hepatitis C is a viral infection that leads to liver inflammation and can result in severe liver damage if not treated. The rise in hepatitis cases is largely attributed to low vaccination coverage, which leaves many individuals vulnerable and enables continued virus transmission. Hepatitis C testing supports early detection of the virus, allowing timely treatment to prevent liver damage and serious complications. It also helps identify infected individuals, supporting efforts to curb transmission and improve disease control. For example, in April 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization responsible for global public health, more than 50 million people worldwide were living with chronic hepatitis C virus infection, with around 1 million new infections reported annually. Therefore, the growing prevalence of hepatitis cases is driving the growth of the hepatitis C testing market.

Major companies operating in the hepatitis C testing market are concentrating on developing advanced solutions, such as dual antigen-antibody diagnostic tests, to improve screening and monitoring of the infection. An antigen-antibody diagnostic test detects both viral proteins (antigens) and immune response proteins (antibodies), enabling identification of current and past infections. This dual-detection approach provides a comprehensive assessment of infection status. For instance, in July 2023, Roche Diagnostics India Pvt. Ltd., an India-based provider of diagnostic tests and systems, introduced Elecsys HCV Duo, a fully automated immunoassay that can simultaneously and independently detect HCV antigens and antibodies from a single plasma or serum sample. This innovation supports early diagnosis, enhances patient management, and aligns with India’s national hepatitis C elimination strategy through timely and comprehensive screening.

In October 2024, QIAGEN N.V., a Netherlands-based molecular diagnostics and sample technologies company, partnered with Bio-Manguinhos/Fiocruz, a Brazil-based public health institution, to strengthen the detection of malaria, dengue, and hepatitis C within Brazil’s national screening programs. Through this collaboration, QIAGEN N.V. and Bio-Manguinhos/Fiocruz aim to improve diagnostic sensitivity, efficiency, and scalability, enabling timely and accurate disease monitoring across the country. Bio-Manguinhos/Fiocruz is a Brazil-based institute specializing in vaccine, diagnostic, and biopharmaceutical development.

Major companies operating in the hepatitis c testing market are F. Hoffmann-La Roche Ltd., Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Quest Diagnostics Incorporated, Hologic Inc., QuidelOrtho Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., SD Biosensor INC., QIAGEN N.V., DiaSorin S.p.A., Cepheid, OraSure Technologies Inc., Meridian Bioscience Inc., Trivitron Healthcare Private Limited, General Biologicals Corporation, Biogate Laboratories Ltd., Cosara Diagnostics Private Limited, BioGenex Life Sciences Private Limited.

North America was the largest region in the hepatitis C testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis c testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatitis c testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the hepatitis c testing market by increasing costs of imported reagents, diagnostic kits, analyzers, and molecular testing equipment used in antibody and nucleic acid testing. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on globally sourced test components, while Asia-Pacific faces pricing pressure on exported diagnostic products. These tariffs raise testing costs and may slow screening expansion in resource-limited settings. However, they also encourage domestic kit manufacturing, regional reagent production, and investment in localized diagnostic supply chains.

The hepatitis c testing market research report is one of a series of new reports that provides hepatitis c testing market statistics, including hepatitis c testing industry global market size, regional shares, competitors with a hepatitis c testing market share, detailed hepatitis c testing market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis c testing industry. This hepatitis c testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hepatitis C testing involves diagnostic methods used to detect HCV infection or the body’s immune response to the virus. These tests help identify both current and past infections, enabling timely treatment. They are especially important for high-risk individuals and assist in monitoring treatment outcomes. Early detection helps lower the risk of serious liver complications such as cirrhosis and liver cancer.

The primary forms of hepatitis C testing include antibody tests, nucleic acid tests, and genotyping tests. Antibody tests are diagnostic procedures that identify the presence of antibodies in the blood, indicating a past or ongoing immune response to infections such as hepatitis C. Available products include test kits, instruments, reagents, and consumables, utilizing test technologies such as enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests, polymerase chain reaction (PCR), and next-generation sequencing (NGS). These tests are applied in areas including blood screening, viral load monitoring, and disease diagnosis, and are used by various end-users such as hospital-based laboratories, stand-alone laboratories, and others.

The hepatitis C testing market consists of revenues earned by entities by providing services such as laboratory-based HCV RNA testing, rapid diagnostic tests, and home-based HCV test kits. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis C testing market also includes sales of quality control materials, sample collection devices, and point-of-care (POC) diagnostic devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.